This clinical trial is focused on studying a condition known as high-risk smoldering multiple myeloma, which is a type of blood disorder that can potentially develop into a more serious form of cancer called multiple myeloma. The study is investigating the effects of a treatment called Elranatamab, which is a solution for injection developed by Pfizer Inc. The main goal of the study is to determine how effective Elranatamab is in treating patients who have not previously received treatment for this condition.

Participants in the study will receive Elranatamab through subcutaneous injections, which means the medication is administered under the skin. In addition to Elranatamab, some patients may also receive other medications such as Dexamethasone, an oral solution that helps reduce inflammation, Diphenhydramine Hydrochloride, an antihistamine tablet used to relieve allergy symptoms, Paracetamol, a tablet for pain relief and fever reduction, and Tocilizumab, an immunosuppressant given as an intravenous infusion to help control the immune system’s activity.

The study will be conducted over a period of time, with regular monitoring to assess the treatment’s effects and any side effects. The primary focus is to see if patients achieve complete remission, which means the disease is no longer detectable, by the end of the sixth cycle of treatment. The study will also monitor for any significant side effects that may occur. This research aims to provide valuable information on the potential benefits of Elranatamab for patients with high-risk smoldering multiple myeloma.